[go: up one dir, main page]

WO1996025147A1 - Composition de liposomes et procede d'administration de medicaments par liposomes - Google Patents

Composition de liposomes et procede d'administration de medicaments par liposomes Download PDF

Info

Publication number
WO1996025147A1
WO1996025147A1 PCT/US1996/002005 US9602005W WO9625147A1 WO 1996025147 A1 WO1996025147 A1 WO 1996025147A1 US 9602005 W US9602005 W US 9602005W WO 9625147 A1 WO9625147 A1 WO 9625147A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
gradient
liposomes
outside
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/002005
Other languages
English (en)
Inventor
Martin C. Woodle
Samuel Zalipsky
Francis J. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Sequus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharmaceuticals Inc filed Critical Sequus Pharmaceuticals Inc
Priority to AU49818/96A priority Critical patent/AU4981896A/en
Publication of WO1996025147A1 publication Critical patent/WO1996025147A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Definitions

  • the present invention relates to a liposome composition and method of use in administering a compound, at high drug concentration, in liposome-encapsulated form.
  • Liposome delivery systems have been proposed for a variety of drugs. Liposome-drug formulations offer the potential of improved drug-delivery properties, such as enhanced blood circulation time and controlled drug release. Liposomes carrying therapeutic agents, such as anti-tumor, imaging agents and the like, have also been shown to be effective for targeting to selected tissues, such as liver, or to non- RES (reticuloendothelial system) tissue, to solid tumors, lymph, and sites of inflammation (Martin, F.J., 1990). Site-specific targeting offers the potential of reducing side-effects and increased dosing at the target site. In preparing liposomes for therapeutic use, it is usually desirable to load high concentrations of drug into the liposomal carrier. In addition, the liposomes should be able to retain the encapsulated drug if improved therapeutic efficacy is to be realized.
  • therapeutic agents such as anti-tumor, imaging agents and the like
  • Liposomes may be passively loaded by adding the drug during hydration of vesicle-forming lipids.
  • the efficiency of passive loading at least in the case of water-soluble drugs, is limited by relatively poor encapsulation efficiency, usually less than about 15% of the total drug present in the hydrating medium. Passive loading also limits the internal concentrations of drug that can be achieved.
  • enhanced drug loading may be achieved by a reverse-phase evaporation method (Szoka, et al., 1980) and can encapsulate up to 50% of active agent.
  • this technology is not readily adaptable to commercial liposome production, because of the requirement for large volumes of volatile solvents.
  • liposomes produced by this technique must be sized down, e.g., by extrusion, for parenteral use. Downsizing is a somewhat inefficient process which leads to further liposome losses.
  • Active drug loading against an ion gradient has also been proposed (Yatvin and Lelkes,
  • the invention includes, in one aspect, a liposomal composition for use in administering to a subject, a compound having a derivatizable hydroxyl group.
  • the compound is one which is substantially uncharged at a neutral pH.
  • the composition includes an external bulk-phase medium and, suspended in the medium, liposomes having an internal aqueous phase at a pH which forms an inside/outside pH gradient with respect to the internal aqueous phase and the external medium.
  • Encapsulated within the liposomes is a compound conjugate composed of the compound to be administered and an adduct conjugated to the compound's derivatizable hydroxyl group by an ester linkage, where the adduct is effective to maintain the compound conjugate in liposome-encapsulated form in response to the pH gradient.
  • the inside/outside pH gradient is a lower inside/higher outside pH gradient.
  • Exemplary adducts for use in the present invention include, for example, amino acids.
  • the amino acid is coupled to the compound through an ester linkage formed between the compound's hydroxyl group and the carboxy 1 group of the amino acid.
  • the compound may be, for example, a radiosensitizer, such as a halogenated deoxyuridine, a nitroimidazole, an anthraquinone, a 2-nitrofuran, a benzoquinone, or a naphthoquinone.
  • a radiosensitizer such as a halogenated deoxyuridine, a nitroimidazole, an anthraquinone, a 2-nitrofuran, a benzoquinone, or a naphthoquinone.
  • the compound may be an anti-viral nucleoside analog, such as 5'-chlorodeoxyuridine, 5'-bromodeoxyuridine, 5'-iododeoxyuridine, or 5'- fluorodeoxyuridine.
  • the lower inside/higher outside pH gradient may be produced by a higher inside/lower outside ammonium ion gradient, preferably where the counterion of an ammonium salt is effective to decrease the solubility of the compound conjugate in the internal aqueous phase.
  • the liposomes are composed predominantly of lipid components having phase transition temperatures above about 37°C.
  • the liposomes are coated with a hydrophilic polymer effective to extend the circulation time of the administered liposomes severalfold over that in the absence of such hydrophilic polymer.
  • the liposomes For enhanced liposomes targeting to a solid tumor target or site of inflammation, the liposomes have sizes predominantly in the range between 0.07 and 0.12 ⁇ m.
  • the invention provides a liposomal composition for use in administering a compound, which includes, encapsulated within the liposomes, an ionizable carboxyl-containing compound conjugate of the compound to be delivered.
  • the compound to be delivered possesses a derivatizable hydroxyl group, and an adduct covalently bonded to the hydroxyl group to form an ester bond, as well as a free carboxylic acid function.
  • Molecular adducts for use in coupling to the hydroxy-containing compound include reactive anhydrides such as succinic and glutaric anhydride, as well as di-carboxylic acids.
  • the free acid portion of the conjugate provides efficient compound-conjugate loading by utilization of a higher inside/lower outside liposome pH gradient.
  • the selected pH of the internal phase of the liposomes is substantially greater than the pKa of the free carboxyl group of the carboxyl-containing compound conjugate, to maintain the compound conjugate in liposome encapsulated form.
  • the invention includes a drug-delivery combination for use in administering to a subject, a compound having a derivatizable hydroxyl group.
  • the combination includes a compound-conjugate composed of the compound to be administered and an adduct conjugated to the derivatizable group of such compound by an ester linkage, and liposomes, which, when suspended in an aqueous medium having a selected pH, possess an internal aqueous environment and an inside/outside pH gradient as described above.
  • the adduct is effective to promote net uptake of the compound into the liposomes in response to the pH gradient.
  • the invention includes a method of preparing a suspension of liposomes for use in delivering a compound having a derivatizable hydroxyl group.
  • the method includes adding to an aqueous suspension containing (i) a bulk phase medium, and (ii) suspended in the bulk phase medium, liposomes having an internal aqueous phase, and an inside/outside pH gradient with respect to the bulk phase medium, a derivatized compound composed of the compound to be delivered, and an adduct attached to the compound's derivatizable group through an ester linkage.
  • the compound and liposome mixture is then incubated under conditions effective to allow passage of the compound from the external medium into the liposomes, with the compound adduct being effective to produce net uptake of the compound conjugate into the liposomes in response to the pH gradient.
  • the incubation is preferably carried out at a temperature substantially above the phase transition temperatures of the liposome-forming lipids.
  • Fig. 1A shows a simplified reaction scheme for forming an ester between the 5'-OH group of a nucleoside analog and the carboxyl group of an amino acid
  • Fig. IB illustrates one a method for forming a conjugate of nucleoside analog and an amino acid
  • Figs. 2A-2F show the structures of representative nucleoside-analog-amino acid conjugates useful in the invention
  • Figs. 3A-3C show the structures of representative radiosensitizer-amino acid conjugates useful in the invention
  • Fig. 4 illustrates the ionization events in loading a compound conjugate into pH gradient liposomes, in accordance with the invention
  • Fig. 5 illustrates the ionization events in loading a compound-conjugate into liposomes, across an ammonium ion gradient
  • Fig. 6 illustrates the ionization events in loading a halodeoxyuridine/carboxyl conjugate into liposomes, across a pH gradient.
  • a "zwitterionic" compound also referred to as a dipolar ion or inner salt, refers to a compound having both acidic and basic functional groups in the same molecule.
  • a zwitterionic species possesses both a cationic and an anionic center, but exhibits no overall net charge within a selected pH range.
  • Compounds containing both an amino group and an acid group may exist as zwitterions whenever the pKa of the protonated amino group is greater than the pKa of the acid.
  • pH's from about 5.5-7.5 the chief species in solution is typically the zwitterionic form of the compound itself.
  • Hydrophill-containing compound refers to any compound which contains at least one reactive -OH group and may contain other functional moieties.
  • a hydroxyl-containing compound may belong to any of a number of structural classes of compounds including nucleoside analogs, nitroimidazoles, anthraquinones, nitrofurans, benzoquinones, and naphthoquinones.
  • a hydroxyl-containing compound (RO-H) that is "substantially uncharged" at neutral pH refers to a compound which is not ionized to any appreciable extent in aqueous solution maintained within a neutral pH range, e.g., 6.5-7.5.
  • the pKa value of a hydroxy-containing compound in accordance with the invention is typically about 13 or greater.
  • the hydroxy- containing compound may contain additional functional groups, so long as the functional groups are not ionizable within a neutral pH range, as described above.
  • “Compound conjugate” refers to the product formed by reacting a hydroxyl group of a compound for use in the present invention with an adduct molecule capable of forming an ester linkage.
  • the ester bond may, in some cases, be biodegradable, i.e., hydrolyzed in vivo.
  • the adduct molecule contains at least one derivatizable carboxyl functionality or a functional group which is readily converted to a carboxyl functionality.
  • Ester linkage refers to the linkage -C(0)-OR formed by any of a number of appropriate synthetic methods including reaction between a carboxylic acid and a hydroxy-containing compound (alcohol), an acid chloride and an alcohol, or by transesterification.
  • External bulk phase medium refers to any external medium in which the liposomes are suspended.
  • Molecular adduct refers to any compound that contains at least one functional group capable of reacting with a hydroxyl function to form a covalent ester linkage.
  • the ester bond between the compound and agent may be biodegradable, e.g. , can be cleaved in vivo by biological or physiological processes, effective to release the compound in an active form.
  • Dicarboxylic acid refers to a compound with two or more carboxylic acid groups, including protected forms thereof.
  • amino acid refers to any compound containing both an amino group and a carboxylic acid group. Although the amino group most commonly occurs at the position adjacent to the carboxy function, the amino group may be positioned at any location within the molecule.
  • the amino acid may also contain additional functional groups, such as amino, thio, carboxyl, carboxamide, imidazole, etc.
  • the amino acids may be synthetic or naturally occurring, and may be used in either their racemic or optically active forms.
  • Alpha carboxyl group of an amino acid refers to the carboxyl group of an amino acid located in the position alpha or adjacent to the amino group.
  • Base amino acid refers to an amino acid containing a second basic group, such as amino (e.g. , lysine), guanidino (e.g. , arginine), or imidazole (e.g. , histidine).
  • amino e.g. , lysine
  • guanidino e.g. , arginine
  • imidazole e.g. , histidine
  • Acidic amino acid refers to an amino acid containing a second carboxyl group (e.g. , glutamic acid, glu) or a potential carboxyl group, such as carboxamide (e.g., asparagine).
  • a “liposome-entrapped” or “liposome-encapsulated” compound refers to a compound which is sequestered in the internal compartment of liposomes.
  • a “surface coating" of hydrophilic polymer chains, such as polyethyleneglycol (PEG), on a liposome refers to the coating of any hydrophilic polymer on the surface of liposomes.
  • the hydrophilic polymer contains from about 20-150 monomer subunits, and more preferably, from 40-100 subunits.
  • Radiosensitizer refers to any chemical agent having the capacity to increase the lethal effects of radiation on biological cells.
  • Lower inside/higher outside pH gradient refers to a transmembrane pH gradient between the interior of liposomes (lower pH) and the external medium (higher pH) in which the liposomes are suspended.
  • the interior-liposome pH is 1-4 pH units lower than the external-medium pH.
  • a “higher inside/lower outside pH gradient” refers to a transmembrane pH gradient between the interior of liposomes (higher pH) and the external medium (lower pH) in which the liposomes are suspended.
  • the interior-liposome pH is 1-4 pH units higher than the external -medium pH.
  • a molecular adduct is coupled to the compound to be administered for use in improving the compound's loading profile, particularly for use in active loading against an ion or pH gradient.
  • the adduct portion of the conjugate may be cleaved under physiological conditions to release the parent compound in an active form, such as by the action of esterases.
  • the active form typically corresponds to the unmodified compound.
  • molecular adducts for use in the present invention are non-toxic, when administered at levels typically contained within the liposomes.
  • the molecular adduct may also provide additional favorable properties to the resulting conjugate, such as enhanced water solubility due to the introduction of one or more ionizable functional groups.
  • adducts containing multiple functional groups selective protection/deprotection may be required to form the desired conjugate.
  • a variety of protected amino acids, amino acid alcohols, and activated amino acid esters may be obtained from Advanced ChemTech, Louisville, KY).
  • adduct molecule is chosen to maintain the conjugate in liposome-encapsulated form in response to a selected pH gradient.
  • the resulting derivatized compound will typically possess an overall net charge (absolute value) of one or greater within a neutral pH range.
  • a nucleoside analog such as a nitroimidazole, anthraquinones, 2-nitrofurans, benzoquinones, naphthoquinones or corticosteroids.
  • the hydroxyl- containing compound or active agent is esterified directly by reaction with the alpha carboxyl group of an N-protected amino acid.
  • the amino group is located adjacent the carboxy function.
  • the amino group of an ionizable moiety may be located at any suitable position within the amino acid molecule.
  • amino protecting groups may be used on the adduct, such as carbobenzoxy (CBZ), tert-butoxycarbonyl (t-BOC), trityl derivatives such as trityl (Tr), dimethoxy trityl (DMTr) and the like (Greene, et al.).
  • Amidine protecting groups such as those formed by reacting an amino group with N,N-dimethylacetamide dimethylacetal, may also be used for protecting the exocyclic amino functions of various nucleosides (McBride, et al., 1983; Froehler, et al., 1983).
  • protecting groups such as cyclic diacyl groups or nitrophenylsulfenyl (Nps) may also provide suitable reagents for protecting amino functions.
  • a suitable protecting group for use in the present invention is one which is easy to introduce into the molecule, protects the amino functional group under the esterification reaction conditions, and is removable under conditions (either acidic or basic) which leave the newly formed ester linkage intact.
  • a suitable condensing agent is typically used, such as dicyclohexylcarbodiimide (DCC) or any appropriate carbodiimide reagent (Holmberg, et al., 1979; Hassner, et al., 1978).
  • the condensing agent is used to activate the carboxy group of the amino acid.
  • 4-dimethylaminopyridine (DMAP) may also be added to the reaction mixture to reduce reaction times and increase yields (Aggarwal, et al., 1990).
  • the reactions are carried out under anhydrous conditions to disfavor the carboxylic acid; a preferred solvent is ethyl acetate.
  • the reactions are typically carried out until complete, as determined by TLC.
  • the reaction times range from about 1-3 days.
  • the N- protected compound-conjugate is then separated from the solid dicyclohexylurea by-product and purified by suitable extractive and chromatographic methods.
  • Deblocking of the purified compound conjugate is typically carried out under acidic conditions, such as with hydrochloric acid in dioxane.
  • Deprotection of the amino group may also be carried out under basic conditions, depending upon the nature and sensitivity of other functional groups present in the compound-conjugate.
  • Examples IB and 1C The preparation of exemplary amino acid conjugates of AZT and 5-bromodeoxyuridine as described above is summarized in Examples IB and 1C, respectively.
  • Representative amino acid adducts used to form the corresponding conjugate compounds include lysine, phenylalanine, 3-alanine, glycine, and 6-aminocaproic acid.
  • Amino acid compounds are readily available, either by synthetic or commercial (Advanced Chem Tech, Louisville, KY; Synthetech, Inc., Albany, OR; Degussa Corp., Ridgefield Park, NJ) sources.
  • the carboxy group of the N-protected amino acid is first transformed to an active ester intermediate.
  • an N- protected amino acid is first reacted with 1-hydroxybenzotriazole in the presence of DCC to form the N-protected benzotriazole ester.
  • Any of a number of transformations may be used to activate the carboxyl group of the N- protected amino acid, for example the carboxyl group may be converted to the corresponding acyl chloride with a suitable chlorinating reagent such as phosphorus trichloride or sulfonyl chloride or the like, or convened to the corresponding anhydride.
  • the activated amino acid reagent preferably the benzotriazole ester
  • the activated amino acid reagent is reacted with the hydroxyl containing compound in the presence of DMAP.
  • a preferred solvent for carrying out the reaction is acetonitrile. Reaction times are typically less than 12 hours.
  • the resultant N-protected compound-conjugate is deblocked under acidic conditions, preferably by mixing with trifluoroacetic acid in methylene chloride.
  • the choice of deblocking reagent will depend upon the presence or absence of other functional groups in the compound-conjugate and their susceptibility to cleavage or reaction under the deprotecting conditions employed.
  • the hydroxyl-containing compound, and particularly the nucleoside analogs may contain more than one hydroxyl moiety.
  • variations in the synthetic method may be employed which take into account the differences in activity of the hydroxyl groups, the proposed position for the esterification, and the like. Protection of additional hydroxyl groups may be required by one of the methods commonly known in the art.
  • the 5-halodeoxyuridine compounds possess more than one hydroxyl group.
  • the 5-halodeoxyuridines possess two hydroxyls, one at the 5 '-position (on a primary carbon atom), and another at the 3 '-position (on a secondary carbon).
  • exclusive formation of the 3'-ester conjugate may be achieved by first protecting the 5'-OH group with an appropriate protecting group, such as trityl or one of the methoxytrityl protecting groups, followed by preparation of the desired ester at the 3' position.
  • exclusive formation of the 5 '-ester may be promoted by first blocking the 5'-hydroxy group, followed by protection of the 3'-hydroxy function with a different protecting group.
  • a preferred blocking group for the 5'-OH group is isobutyloxycarbonyl, while 4-methoxytrityl may be used for protection of the 3 '-group (Saari, et al., 1990).
  • the di-protected alcohol is then reacted with the activating agent, such as benzotriazole or the like, which should then react preferably at the 5 '-protected function of the nucleoside to form the desired product.
  • Figs. 2A-2F show the structures of representative nucleoside analogue-amino acid conjugates in accordance with the present invention.
  • Fig. 2A illustrates the structure of the nucleoside analogue, minimycin, (also known as oxazinomycin) coupled to the amino acid, isoleucine.
  • Fig. 2B illustrates a synthetic hydroxy-pyridinone, 3-deazauridine, coupled via its 5'-hydroxy function to the molecular adduct, alanine.
  • the nucleoside analogue, 6-azauridine is coupled to leucine to form an ionizable compound conjugate for efficient loading into pH gradient liposomes.
  • Fig. 1 illustrates the structure of the nucleoside analogue, minimycin, (also known as oxazinomycin) coupled to the amino acid, isoleucine.
  • Fig. 2B illustrates a synthetic hydroxy-pyridinone, 3-deazauridine, coupled via its 5'-
  • FIG. 2D shows the nucleoside analogue, ARA-T, coupled to the amino acid, phenylalanine.
  • Fig. 2E shows a hydroxy-containing compound coupled to an amino acid adduct.
  • Fig. 2F illustrates 6-azathymidine coupled to the amino acid valine.
  • Fig. 2F Another exemplary compound conjugate is shown in which the nucleoside analogue, 2 * 3'-didehydro-3'- deoxythymidine is coupled to the amino acid, glycine.
  • These representative compound conjugates are efficiently loaded into pH gradient liposomes and further maintained in liposome-encapsulated form, in accordance with the present invention. Preparation of both the 5'- and 3'- mono amino acid esters, as well as the 5',3'-diamino acid esters of 5-bromodeoxyuridine, is described in Examples IB and 1C, respectively.
  • reagents may also be employed to form the compound-conjugates of the present invention.
  • polymer-bound DMAP with DCC to promote formation of an ester linkage between a hydroxy-containing compound and a carboxylic acid.
  • Sulfonyl chloride and sulfonyl chloride type reagents may also be used. Reagents of this type include fluorosulfonyl chloride (S0 2 C1F) and triethylamine; and methylsulfonyl chloride and triethyl amine (a reagent system useful for unsaturated reactants).
  • Phosphorus-containing reagents for use in forming esters include PhOP(0)Cl 2 in DMF and Bu 3 PL in ether and HMPT.
  • hydroxyl-containing nucleoside and nucleotide analogs have activity as chemical radiosensitizers, anti-viral agents, and anti-tumor drugs.
  • One such anti-viral nucleotide analog is ribavarin-5'-sulfamate, which has been shown to inhibit Semliki Forest virus in-vitro and in mice (Martin, J., p. 136-137, 1989).
  • Ribovarin is a broad spectrum nucleoside analog that is active against a number of RNA and DNA viruses (Martin, J., p. 18, 19, 1989).
  • Base-modified nucleoside analogs such as the halogenated pyrimidines, 5- iododeoxyuridine (IUdR), 5-bromodeoxyuridine (BUdR), 5-chlorodeoxyuridine (CUdR), and 5-fluorodeoxyuridine (FUdR), trifluorothymidine, dideoxyinosine (DDI), minimycin, 3- deazauridine, 6-azathymidine, and ribavirin.
  • Trifluorothymidine and IUdR are active mainly against herpes viruses (Nicholson, 1984a, 1984b).
  • Ribavirin is active against several RNA and DNA viruses (Sidwell).
  • the halogenated 5-deoxyuridine compounds, IUdR, BUdR, CUdR, and FUdR, are modifiers of radiosensitivity but are not specific to hypoxic cells (Shenoy, et al., 1992). These compounds are incorporated into the DNA chain in place of thymidine, thereby rendering the DNA more susceptible to radiation treatment.
  • nucleoside analogs include sugar-modified nucleoside analogs, such as N-acyl derivatives of 5'-amino-2',5'-dideoxy 5'-iodouridine, 3'-azido-2',3'-dideoxythymidine (AZT), acyclovir, ganciclovir, dideoxycytidine (DDC), dideoxyinosine (DDI, both base and sugar modified), 2', 3 '-didehydro-3'-deoxy thymidine (D4T), sulfonamide derivatives of 5'-amino-5'- deoxy thymidine, 2'-deoxy-5-ethyluridine, and N-acyl derivatives, AraA, ARA-T, 5'-sulfate and 5'-sulfamate nucleoside analogs, such as nucleocidin, adenosine 5' sulfamate, and ribavarin-5-sulf
  • ARA-T has been reported to inhibit the replication of HSV-1 and HSV-2 (Walker); d4T has been shown to inhibit the replication of HIV.
  • AZT is active against HIV (Fischl), as are other dideoxynucleoside analogs, such as DDI.
  • Acyclovir is active against herpes simplex 1 and 2 and varicella zoster (Fishl, et al., 1987); ganciclovir, an analog of acyclovir, is active against HSV-1 , HSV-2, varicella zoster as well cytomegalovirus, CMV (Smith, et al., 1982).
  • Nucleoside phosphate/phosphonate analogs include acyclonucleoside phosphonates and phosphates such as those of acyclovir and ganciclovir. These compounds can act as virus- selective substrates for viral thymidine kinases in the synthesis of nucleoside triphosphate analogs intracellularly (Galbraith, et al., 1969). Subsequently, the nucleoside triphosphate analogs can act as selective substrates for viral DNA polymerase, thereby functioning as chain terminators due to their lacking the bifunctionality necessary for chain extension (Allen, et al., 1983).
  • phosphonomethyl ethers of nucleosides and their acyclic analogs, such as N-(3-hydroxy-2-phosphonylmethoxypropyl)- (HPMP-) and N-(2- phosphonylmethoxyethyl-)(PME-) derivatives of heterocyclic bases.
  • HPMP- N-(3-hydroxy-2-phosphonylmethoxypropyl)-
  • PME- N-(2- phosphonylmethoxyethyl-) derivatives of heterocyclic bases.
  • These compounds act specifically against herpes viruses, adenoviruses, cytomegalovirus (DeClercq, 1988), poxviruses, vaccinia viruses, and retroviruses.
  • Radiosensitizers are chemical agents that have the capacity to increase the lethal effects of radiation when administered in conjunction with radiation, typically for use in cancer therapy. Ideally, they should increase radiation sensitivity without being toxic.
  • the potential usefulness of the 5'- halodeoxyuridines is limited by a number of factors (Shenoy, et al., 1992).
  • the drugs In order to provide effective therapy, the drugs must be present in the bloodstream for a period long enough to allow the cells to pass through at least one DNA synthesizing cycle.
  • the rapid hepatic degradation and dehalogenation must be overcome.
  • the liposome composition of the invention, and particularly the liposome formulation employing hydrophilic polymer derivatized lipids provides an enhanced mode of delivery of this class of radiosensitizers by providing enhanced circulation times and protecting the compound from dehalogenation by encapsulation within the liposome bilayer.
  • halogenated 5'-deoxyuridines In addition to the halogenated 5'-deoxyuridines, several other types of compounds are known to possess radiosensitizing activity. Many of these compounds possess functional groups which can act as electron acceptors, such as carbonyl, aldehyde, nitro, or cyano groups which are attached to an aromatic or heterocyclic ring. These electron-affinic compounds are specific for hypoxic tumor cells (Adams, 1992). 13
  • bioreductive drugs compounds that are chemically reduced intracellularly to form active cytotoxic agents
  • compounds may function as both radiosensitizers and bioreductive agents.
  • Bioreductive compounds may be useful as agents in selective chemotherapy targeted against solid tumors (Adams, 1992). This is due to the fact that bioreduction is often favored under hypoxic conditions and hypoxic cells have been shown to exist in most murine tumors and several human tumors (Shenoy, et al., 1992).
  • Classes of compounds which are classified as either radiosensitizers or bioreductive compounds include nitro-containing heterocycles such as the nitroimidazoles (e.g. , metronidazole, misonidazole, etanidazole, nimorazole); nitrofurans (e.g., nifurpipone); fused ring quinones such as benzoquinones, anthraquinones, naphthoquinones and the like (e.g. E09); and organic N-oxides.
  • Representative radiosensitizer compound-amino acid conjugates useful in the present invention are shown in Figs. 3A-3C.
  • the exemplary radiosensitizer compounds illustrated are 5-iododeoxyuridine, misonidazole, and E09 (Adams), respectively.
  • a third general class of compounds include anti-inflammatory compounds, including steroidal anti-inflammatory drugs.
  • Steroidal compounds for use in the invention include the hydroxyl-containing corticosteroidal compounds, prednisone, methylprednisolone, paramethazone, 11-fludrocortisol, triamcinolone, betamethasone and dexamethasone.
  • Such anti-inflammatory compounds when coupled through a reactive group to an adduct molecule effective to maintain the conjugate in liposome entrapped form, are suitable for delivery by the liposome composition of the present invention, particularly by IV administration.
  • the compound is useful, preferably, for treating inflammation and particularly for inflamed dermal tissue.
  • the liposomes of the invention are composed of vesicle-forming lipids, generally including amphipathic lipids having both hydrophobic tail groups and polar head groups.
  • a characteristic of a vesicle-forming lipid is its ability to either (a) form spontaneously into bilayer vesicles in water, as exemplified by the phospholipids, or (b) be stably incorporated into lipid bilayers, by having the hydrophobic portion in contact with the interior, hydro- phobic region of the bilayer membrane, and the polar head group oriented toward the exterior, polar surface of the membrane.
  • the vesicle-forming lipids of this type are preferably those having two hydrocarbon tails or chains, typically acyl groups, and a polar head group. Included in this class are the phos ⁇ pholipids, such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA), phosphatidylglycerol (PG), and phosphatidylinositol (PI), where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.
  • Preferred phospholipids include PE and PC.
  • An exemplary PC is hydrogenated soy phosphatidylcholine (HSPC).
  • Single chain lipids, such as sphin- gomyelin (SM) may also be used.
  • glycolipid as used herein encompasses lipids having two hydrocarbon chains, one of which is the hydrocarbon chain of sphingosine, and one or more sugar residues.
  • Lipids for use in the present invention may be relatively "fluid" lipids, meaning that the lipid phase has a relatively low lipid melting temperature, e.g., at or below room temperature, or alternately, relatively “rigid” lipids, meaning that the lipid has a relatively high melting point, e.g. , at temperatures up to 50 °C.
  • relatively rigid i.e. , saturated lipids
  • Preferred lipids of this type are those having phase transition temperatures above about 37°C.
  • the liposomes may additionally include lipids that can stabilize a vesicle or liposome composed predominantly of phospholipids.
  • the most frequently employed lipid from this group is cholesterol at levels between 25 to 40 mole percent.
  • cholesterol When cholesterol is present at between 0 to 20 mole percent in a bilayer, undesirable separate domains containing cholesterol and phospholipids and pure phosphoiipid may exist (Mabrey, et al., 1978). These bilayers show an increased permeability to water (Tsong, 1975). At mole percentages above 50%, cholesterol may contribute to destabilizing the bilayer.
  • the liposomes may also include a coating of a hydrophilic polymer chain.
  • Liposomes thus prepared may include one or more vesicle-forming lipids derivatized with a hydrophilic polymer chain.
  • the vesicle-forming lipids which can be used are any of those described above for the first vesicle-forming lipid component.
  • Vesicle-forming lipids with diacyl chains, such as phospholipids, are preferred.
  • One preferred phosphoiipid is phosphatidylethanolamine (PE), which contains a reactive amino group convenient for coupling to the activated polymers.
  • PE phosphatidylethanolamine
  • DSPE distearyl PE
  • a preferred hydrophilic polymer for use in coupling to a vesicle forming lipid is polyethyleneglycol (PEG), preferably as a PEG chain having a molecular weight between 1,000-10,000 daltons, more preferably between 2,000 and 5,000 daltons.
  • PEG polyethyleneglycol
  • Examples 2 and 3 present the synthesis of one preferred liposome-type for use in the present invention, namely, long circulating liposomes composed of PEG-PE, HSPC and cholesterol. The details of the synthesis are described therein.
  • hydrophilic polymers which may be suitable include polylactic acid, polyglycolic acid, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydi ethylacrylamide, and derivatized celluloses, such as hydroxymethylcellulose or hydroxyethylcellulose.
  • Lipid-polymer conjugates containing these polymers attached to a suitable lipid, such as PE are described in co-owned U.S. Patent No. 5,395,619, (issued on 7 March 1995).
  • An exemplary method of preparing a PE-PEG compound is described in Examples 2A and 2B.
  • a capped polyalkylether polyethylene glycol methyl ether
  • a carbonyl diimidazole reagent to form the activated carbamate.
  • an amino-containing lipid such as PE
  • the hydrophilic polymer chains provide a surface coating of hydrophilic chains sufficient to extend the blood circulation time of the liposomes in the absence of such a coating.
  • the extent of enhancement of blood circulation time is severalfold over that achieved in the absence of the polymer coating, as described in co-owned US patent No. 5,013,556.
  • the liposomes may be prepared to contain surface groups, such as antibodies or antibody fragments, small effector molecules, and the like, for achieving desired target- binding properties.
  • Liposomes with the desired pH gradient may be prepared by a variety of techniques. In a typical procedure, a mixture of liposome-forming lipids is dissolved in a suitable organic solvent and evaporated in a vessel to form a thin film. The film is then covered with an aqueous medium containing the solute species that will form the aqueous phase in the liposome interior spaces, in the final liposome preparation, as discussed below. The lipid film hydrates to form multi-lamellar vesicles (MLVs), typically with heterogeneous sizes between about 0.1 to 10 microns.
  • MLVs multi-lamellar vesicles
  • Liposomes used in the invention typically contain between 30-75 percent phospholipids, preferably phosphatidylcholine (PC), 25-40 percent cholesterol, and 1-20 percent polymer- derivatized lipid, expressed on a molar percent basis.
  • PC phosphatidylcholine
  • One exemplary "rigid" liposome formulation is formed of polyethylene glycol conjugated phosphatidylethanolamine, PEG-PE, hydrogenated soy phosphatidylcholine (HSPC) and cholesterol in a weight ratio of 1:3: 1.
  • Two exemplary fluid liposome compositions contain the components PEG-PE, egg phosphatidylcholine (EPC), and cholesterol, in corresponding molar ratios of 6:56:38 and 6:62:32.
  • the vesicles may be sized to achieve a size distribution of liposomes within a selected range, according to known methods.
  • the liposomes are preferably uniformly sized to a selected size range between 0.04 to 0.25 ⁇ m.
  • Small unilamellar vesicles (SUVs) typically in the 0.04 to 0.08 ⁇ m range, can be prepared by extensive sonication or homogenization (Martin, 1990) of the liposomes.
  • Homogeneous size liposomes having sizes in a selected range between about 0.08 to 0.4 microns can be produced, e.g., by extrusion through polycarbonate membranes or other defined pore size membranes having selected uniform pore sizes ranging from 0.03 to 0.5 microns, typically, 0.05, 0.08, 0.1, or 0.2 microns.
  • the pore size of the membrane corresponds roughly to the largest size of liposomes produced by extrusion through that membrane, particularly where the preparation is extruded two or more times through the same membrane.
  • the sizing is preferably carried out in the original lipid-hydrating buffer, so that the liposome interior spaces retain this medium throughout the initial liposome processing steps.
  • Liposomes having a lower inside/higher outside pH gradient are typically prepared as described below. After sizing, the liposome suspension is treated to adjust the pH of the external medium to a selected pH above that of the internal pH, or to replace the external bulk-phase medium with a medium which will create the desired lower inside/higher outside pH gradient in the final suspension.
  • Exchange of the external bulk-phase medium in a liposome suspension is carried out conventionally, e.g., by dialysis against the desired final medium, molecular sieve chromatography in the desired medium, e.g., using Sephadex G-50, or high-speed centrifugation and resuspension of pelleted liposomes in the desired final medium.
  • the external medium which is selected will depend on the mechanism of pH gradient formation and the external pH desired, as will now be considered.
  • the hydrated sized liposomes have a selected internal-medium pH.
  • the suspension of the liposomes is titrated until a desired final pH is reached, or treated as above to exchange the external phase buffer with one having the desired external pH.
  • the original medium may have a pH of 5.5, in a selected buffer, e.g., glutamate or phosphate buffer, and the final external medium may have a pH of 8.5 in the same or different buffer.
  • the internal and external media are preferably selected to contain about the same osmolarity, e.g., by suitable adjustment of the concentration of buffer, salt, or low molecular weight solute, such as sucrose.
  • the gradient is produced by including in the liposomes, a selected ionophore.
  • liposomes prepared to contain valinomycin in the liposome bilayer are prepared in a potassium buffer, sized, then exchanged with a sodium buffer, creating a potassium inside/sodium outside gradient. Movement of potassium ions in an inside-to-outside direction in turn generates a lower inside/higher outside pH gradient, presumably due to movement of protons into the liposomes in response to the net electronegative charge across the liposome membranes (Deamer).
  • the proton gradient used for drug loading and retention is produced by creating an ammonium ion gradient across the liposome membrane, as described, for example, in U.S. Patent No. 5,192,549.
  • the liposomes are prepared in an aqueous buffer containing an ammonium salt, typically 0.1 to 0.3 M ammonium salt, such as ammonium sulfate, at a suitable pH, e.g., 5.5 to 7.5.
  • the external medium is exchanged for one lacking ammonium ions, e.g., the same buffer but one in which ammonium sulfate is replaced by NaCl or a sugar that gives the same osmolarity inside and outside.
  • ammonium ions inside the liposomes are in equilibrium with ammonia and protons. This equilibrium is continuously shifted toward production of protons by the escape of ammonia from the liposome interiors.
  • ammonium ion gradient provides a number of advantages in active drug loading over the other two approaches given above. Among these are:
  • the system is able to generate protons in response to drug loading, such that the ability to load drugs is not limited by the initial concentration of protons or initial pH gradient. That is, as drug molecules in non-protonated form are taken up and protonated within the liposomes, the loss of protons within the liposomes shifts the ammonium/ammonia equilibrium toward ammonia and proton production, maintaining the concentration of protons at a relatively constant level independent of amount of drug loaded. The only requirement is that the initial ammonium ion concentration within the liposomes is in substantial molar excess of the final loaded drug concentration.
  • the system is able to act like a battery during liposome storage, replacing protons that may be lost by diffusion out of the membranes with newly produced protons, as the ammonium ammonia equilibrium is shifted toward ammonia production. This allows for stable drug retention in liposomes for periods of up to several months in a liquid- suspension form.
  • the counterion of the ammonium salt e.g., sulfate counterion, may further enhance drug loading, by its ability to precipitate or form insoluble complexes with the drug being loaded.
  • This section describes the compound loading method of the invention, and the composition formed by the method.
  • the method includes adding to an aqueous suspension of pH gradient liposomes of the type described above, a derivatized compound composed of the compound to be delivered, and an adduct attached to the compound's derivatizable group through an ester linkage.
  • the components are incubated under conditions effective to allow passage of the compound from the external medium into the liposomes, where the presence of said adduct is effective to produce net uptake of the compound conjugate into the liposomes in response to said pH gradient. That is, the compound in the absence of the adduct is not actively loaded into such liposomes or is loaded relatively poorly.
  • Fig. 4 illustrates the manner of drug loading of a derivatized drug conjugate into liposomes containing a pH gradient.
  • the derivatized compound here is shown with an amine adduct that thus provides an ionizable group capable of forming a positive charge.
  • the drug exists in equilibrium with its protonated ammonio form in the external liposomal environment.
  • neutral-charge drug conjugate diffusing across the liposomal membrane is shifted toward its protonated, charged, non-diffusible form, and thus accumulates in the liposomes.
  • Fig. 5 illustrates loading of a derivatized drug, exemplified by a halo-deoxyuridine-amine conjugate into liposomes against an ammonium ion gradient.
  • the gradient is effective to generate excess internal protons through a mechanism involving dissociation of ammonium and escape of ammonia.
  • the derivatized compound in uncharged form enters the liposomes, its equilibrium is shifted toward a protonated form, due to the higher concentration of internal protons, and in this charged form, leading to net accumulation of compound in the liposomes.
  • the protonated form of the drug can form a complex or precipitate with the ammonium salt counterion (CI )
  • the compound is further driven toward an entrapped state, increasing the concentration of compound that can be entrapped, and the stability of drug entrapment.
  • the solubility of a derivatized compound in various ammonium-salt counterions can be determined by standard methods, for purposes of selecting a counterion which will lead to complex formation and enhanced drug entrapment.
  • Incubation conditions suitable for drug loading are those which (i) allow diffusion of the derivatized compound, with such in an uncharged form, into the liposomes, and (ii) preferably lead to high drug loading concentration, e.g., 50-200 mM drug encapsulated.
  • the loading is preferably carried out at a temperature above the phase transition temperature of the liposome lipids.
  • the loading temperature may be as high as 60°C or more.
  • the loading period is typically between 15-120 minutes, depending on permeability of the derivatized drug to the liposomes, temperature, and the relative concentrations of liposome lipid and drug.
  • the final internal .external concentration of drug will be about 1000: 1. Knowing the calculated internal liposome volume, and the maximum concentration of loaded drug, one can then select an amount of drug in the external medium which leads to substantially complete loading into the liposomes.
  • the liposome suspension may be treated, following drug loading, to remove non-encapsulated drug.
  • Free drug can be removed, for example, by molecular sieve chromatography, dialysis, or centrifugation.
  • Example 4A describes a method for preparing rigid and fluidic PEG-coated liposomes having an ammonium sulfate gradient of about 250 mM [NH 4 ] 2 S0 4 inside, and near 0 mM ammonium salt outside.
  • the liposomes were loaded in the presence of an equal concentration of either AZT-amino acid conjugate or 5'-bromodeoxyuridine-amino acid conjugate in 10% sucrose buffer, at final drug concentrations of 2.5 mg/ml. After loading and removal of free compound-conjugate, the liposomes were analyzed to determine i) the percent of encapsulated nucleoside analog-amino acid conjugate, and ii) percent of nucleoside analog-amino acid conjugate recovered. The loading efficiencies are reported in Tables I and II in Example 4.
  • the invention includes the combination of the above-described pH gradient liposomes and derivatized compound for use in the method. The two components are typically supplied and stored separately, for combining at the site of intended use, e.g., a clinical site, to yield a suspension of compound-loaded liposomes.
  • the combination is advantageous particularly where the drug-loaded liposomes have a relatively high rate of drug leakage, after loading, precluding extended storage time in liquid suspension, or where it is impractical to store the drug-loaded liposomes in dried, e.g. , lyophilized form.
  • the compound-loaded liposome composition prepared as above is stable on storage in liquid suspension form over an extended period, e.g., several months, it may be supplied and stored in this preloaded form.
  • Factors which contribute to storage stability in suspension are: (i) compound stability, both in terms of the ester bond used for compound derivatization and stability of the compound itself against oxidative or other degradative processes in solution; (ii) liposome stability in suspension, typically related to the degree of lipid saturation, and (iii) slow compound leakage from the liposomes.
  • Drug stability in solution can be determined from stability studies, e.g., under accelerated conditions of elevated temperature, according to known procedures. If necessary, drug- protective agents, such as ⁇ -tocopherol, may be added to enhance compound stability on storage.
  • drug- protective agents such as ⁇ -tocopherol
  • Liposome stability in liquid suspension can be enhanced by the use of saturated, high- phase transition lipid components, and optionally by inclusion of such protective agents as a- tocopherol or an iron-chelating agent, such as desferioxamine.
  • Drug leakage from liposomes can be minimized by use of high-phase transition lipids, as discussed above, by maintaining excess protons in the encapsulated space and. if possible, by employing an internal salt counterion that is effective to remove encapsulated compound out of the solute phase.
  • composition containing a derivatized compound loaded within its interior spaces may be stored in lyophilized form.
  • the composition here preferably includes a cr oprotectant, such as a mono- or disaccharide, added to the external medium.
  • a hydroxyl-containing compound to be delivered by liposomes is modified to contain a carboxy group linked to the compound through an ester linkage. This allows loading of the transformed, ionizable compound against a higher inside/lower outside liposome pH gradient, or a reverse pH gradient.
  • the hydroxyl-containing drug is modified by linking the drug's hydroxyl-group to a di- carboxylic acid or a similarly suitable difunctional adduct.
  • a suitable adduct for use in this aspect of the invention is one: i) that possesses at least one functional group capable of reacting with a drug hydroxyl group to form an ester linkage, and ii) has at least one carboxylic acid group, or results in a carboxyl group upon coupling to the drug molecule.
  • Such molecules include dicarboxylic acids and reactive cyclic anhydrides, such as succinic, glutaric and phthalic anhydride.
  • the resulting conjugate, possessing an ionizable carboxy group is maintained in liposome-encapsulated form by selection of an appropriate pH gradient.
  • the pH of the internal phase of the liposomes is substantially greater than the pKa of the conjugate carboxylic acid group, and preferably by at least 1 to 2 pH units.
  • One method for modifying a hydroxy-containing compound to a carboxyl-containing molecule is to couple the compound with an ionizable moiety such as a di-carboxylic acid (or the corresponding cyclic anhydrides, such as glutaric or succinic anhydride) to form the corresponding mixed acid-ester.
  • ester linkage may be sensitive to acidic conditions, such as the endosomal compartment of cells to which such liposomes are targeted.
  • acidic conditions such as the endosomal compartment of cells to which such liposomes are targeted.
  • the conventional compound may then be released in its active form to the desired target site.
  • one of the acid groups of the diacid adduct is protected with a suitable protecting group to prevent ester formation at both reactive -COOH moieties of the adduct.
  • a suitable protecting group will be guided by the consideration that the protecting group must be one that is removable under conditions that leave the newly formed ester-bond between the hydroxy-compound and the molecular adduct intact.
  • the protecting group is cleaved from the adduct portion of the conjugate to generate a free carboxylic acid group, which may then be utilized to promote active ion-gradient loading as described above.
  • a cyclic acid anhydride reagent may be used for coupling to the drug, to form the mixed acid-ester conjugate.
  • Synthesis of the corresponding 5'-,3'-difunctionalized conjugates formed by reacting iododeoxyuridine with either glutaric or succinic anhydride is described in Examples 5A and 5B, respectively.
  • the resulting conjugates possess carboxyl- containing side chains at both the 5'- and 3'- positions of the 2'-deoxyribose ring.
  • the monofunctionalized 5'- or 3'- conjugates may also be formed by the use of suitable protecting groups, as described above.
  • the carboxylic acid groups of the resulting conjugates are separated from the ester carbonyl carbons by either two or three intervening methylenes, depending upon the choice of cyclic anhydride reagent.
  • di-glutaryl and di-succinyl adducts of iododeoxyuridine may be afforded by reacting iododeoxyuridine with either glutaric or succinic anhydride in the presence of DMAP.
  • compounds containing a primary hydroxyl functionality may be oxidized to the corresponding carboxylic acid; secondary and tertiary hydroxyl groups are unaffected.
  • Such compounds may be transformed to possess a carboxy group either for coupling via an ester linkage to a suitable hydroxy-containing adduct or to introduce an ionizable function to the compound to allow liposomal loading against a pH gradient.
  • Oxidants for this purpose include permanganate salts such as sodium permanganate, potassium permanganate and copper permanganate.
  • This approach may also be utilized to transform aldehyde compounds to the corresponding acids.
  • Reagents for this purpose include sodium permanganate, Ca(OCl) 2 , (bipy)H 2 CrOCl 5 , and the like.
  • the safety and efficacy of the resulting modified compound should be verified prior to liposome loading for use in administering to a subject.
  • Liposomes having a reverse pH gradient are prepared substantially as above, but under conditions that lead to a reverse gradient.
  • the liposomes are prepared by hydration in the higher pH medium, e.g., pH 6-9, then treated to adjust the external pH to the selected lower pH. This may be accomplished by addition of an acid to the desired pH.
  • the external medium of the liposomes suspension is exchanged with a lower pH medium.
  • the pH of the internal phase of the liposomes is substantially greater than the pKa of the free carboxylic acid group, and preferably by at least 1-2 units above this pK. value.
  • the external medium is likewise below this pK a .
  • the liposomes are prepared in the presence of a bicarbonate salt, e.g., 200 mM sodium bicarbonate at a selected pH, e.g. , 5-9.
  • a bicarbonate salt e.g. 200 mM sodium bicarbonate at a selected pH, e.g. , 5-9.
  • the external medium is exchanged for buffer lacking bicarbonate ions, e.g. , the same buffer, but one in which sodium bicarbonate sulfate is replaced by NaCl or a sugar that gives the same osmolarity inside and outside.
  • a reverse gradient may be established by a number of different mechanisms. For instance, bicarbonate ions inside the liposomes are in equilibrium (to a small degree) with C0 2 (arising from the corresponding conjugate acid, carbonic acid) and hydroxyl ions. The equilibrium may be shifted toward production of hydroxyl ions by the escape of C0 2 from the liposome interiors, thus generating a higher internal pH. Carbonic acid, due to its small size, may also readily diffuse out of the liposome interior, also shifting the equilibrium towards hydroxyl production. Depending upon the pH of the liposome interior, bicarbonate, in the presence of excess protons (or a source of protons, such as from the compound conjugate), is in equilibrium with carbonic acid.
  • loss of carbonic acid either by conversion to carbon dioxide gas or diffusion, shifts the equilibrium towards consumption of bicarbonate ions and provides a driving force for loading high concentrations of drug conjugate.
  • the accumulation of sodium counterions in the liposome interior may result in an outflow of protons, resulting in a liposome interior having a lower concentration of protons than in the external bulk phase.
  • bicarbonate ion gradient provides advantages in active drug loading, in reverse pH gradient liposomes, similar to the advantages provided by an ammonium ion gradient.
  • ammonium ion gradient provides advantages in active drug loading, in reverse pH gradient liposomes, similar to the advantages provided by an ammonium ion gradient.
  • the system is able to generate hydroxyl ions in response to drug loading, such that the ability to load drugs is not limited by the initial concentration of hydroxyl ions or the initial pH gradient.
  • the system is able to function like a battery during liposome storage, either by replacing hydroxyl ions that may be lost by diffusion out of the membranes with newly produced ions, or by producing an outflow of protons, as the bicarbonate/C0 2 equilibrium is shifted toward C0 2 production.
  • the carboxyl-containing drug initially present only in the external liposomal environment and primarily in its acid form (uncharged), diffuses readily into the liposomes, where the higher internal pH shifts the ionization state of the compound toward its charged, deprotonated form.
  • the loading events are illustrated in Fig. 6 for loading of a representative halodeoxyuridine carboxy conjugate. Loading conditions are substantially like those described above in Section IV.
  • the invention allows a variety of important classes of therapeutic drugs to be loaded into liposomes at substantially higher loading efficiencies and internal drug concentrations than has been possible heretofore.
  • the invention allows for remote compound loading at the site, such that the compound to be loaded, and optionally, pH gradient liposomes, can be supplied and stored in lyophilized form and loaded to high compound concentration directly before use.
  • compounds administered in accordance with the invention are in an esterified form which may be designed, by suitable adduct selection, to enhance the pharmacokinetic properties of the drug and/or reduce side effects.
  • N-protected t-BOC amino acids lysine, phenylalanine, glycine, and 3-alanine, as well as t-BOC aminocaproic acid were purchased from Sigma (St. Louis, MO).
  • Iododeoxyruridine was purchased from Sigma.
  • 1,3-dicyclohexylcarbodiimide was purchased from Aldrich (Milwaukee, WI).
  • Glutaryl anhydride and succinic anhydride were purchased from Lancaster (Windham, NH).
  • DMAP was purchased from Nepera, Inc. (Harriman, NY).
  • Polyethylene glycol methyl ether 1900 was purchased from Aldrich Chemical Company. Cholesterol was obtained from Sigma.
  • EPC Egg phosphatidylcholine
  • HSPC partially hydrogenated soy PC having the compositions IV40, IV30, IV20, IV10, and IV1, phosphatidylglycerol (PG), phosphatidylethanolamine (PE), dipalmitoyl-phosphatidyl glycerol (DPPG), dipalmitoyl PC (DPPC), dioleyl PC (DOPC), and distearoyl PC (DSPC) were obtained from Avanti Polar Lipids (Birmingham, Ala) or Austin Chemical Company (Chicago, 111).
  • PG phosphatidylglycerol
  • PE phosphatidylethanolamine
  • DPPG dipalmitoyl-phosphatidyl glycerol
  • DPPC dipalmitoyl PC
  • DOPC dioleyl PC
  • DSPC distearoyl PC
  • ⁇ NMR spectra of the nucleoside-amino acid esters were obtained using a Nicolet spectrometer operating at 360 mHz. Samples were dissolved in deuterated chloroform or deuterated methanol, tetramethylsilane (TMS) was used as an internal standard.
  • TMS tetramethylsilane
  • Liposome particle size distribution measurements were obtained by dynamic light scattering (DLS) using a Coulter N4MD instrument.
  • control experiments were first carried out to examine the possibility of side reactions occurring at the heterocyclic moieties of AZT and bromodeoxyuridine and to investigate the possibility of side reactions involving the 5- bromo substituent of BrdU.
  • Example ID One set of reactions was carried out as in Example ID except for the ratios of reactants used.
  • the reaction products were consistent with those observed in Examples IB, and ID.
  • the reactions were carried out under anhydrous conditions using dicyclohexylcarbodiimide (DCC) as the condensing agent in the presence of 4-dimethylaminopyridine (DMAP) as a catalyst.
  • DCC dicyclohexylcarbodiimide
  • DMAP 4-dimethylaminopyridine
  • 1.2 equivalents of DCC were added to a stirred solution containing 1.0 equivalents of AZT, 1.1 equivalents of the t-BOC amino acid, and 1.5 equivalents of DMAP in ethyl acetate.
  • the reaction mixture was stirred for about 3 days at room temperature.
  • the resultant mixture was then filtered to remove the dicyclohexylurea side product and the filtrate was washed sequentially to remove unwanted impurities.
  • Residual amino acid was extracted from the reaction solution with a 0.2 M carbonate/bicarbonate solution, followed by washing with a 0.2 M sodium chloride solution.
  • Unreacted DMAP was extracted by washing with an aqueous solution of citric acid.
  • the product was purified by column chromatography over silica gel using an eluent gradient of 1:1, 2: 1, 4: 1, 6: 1, and 8.5: 1 ethyl acetate-hexane.
  • the purified ester conjugate was deblocked by reaction with 4 M HC1 in dioxane.
  • the 5 '-amino acid esters of AZT were prepared by reacting AZT with an activated amino acid ester to improve reaction times and yields.
  • the dicyclohexylurea by-product was removed by filtration and the resultant reaction mixture was extracted with a 1 : 1 solution of 1 M carbonate/bicarbonate at pH 10 to remove any remaining impurities, as determined by TLC.
  • the organic phase was dried over magnesium sulfate.
  • the purified ester was recovered as a white crystalline solid by removal of ethyl acetate solvent by evaporation under reduced pressure. Reaction of t-BOC glycine with HOBT failed to form the desired activated ester.
  • the isolated benzotriazole ester was then dissolved in acetonitrile and reacted with AZT in the presence of DMAP by stirring for about 12 hours at room temperature. Upon completion, the reaction mixture was evaporated to dryness and the crude product was dissolved in a minimal amount of methylene chloride. The organic phase was extracted with a 1 M solution of carbonate/bicarbonate, followed by extraction with a 10% aqueous solution of citric acid to remove impurities. The methylene chloride layer was dried over magnesium sulfate and the solvent removed by evaporation. The N-protected conjugate product was determined to be essentially pure by TLC.
  • the N-protected amino acid-AZT ester was dissolved in a minimum volume of a 1:1 trifluoroacetic acid (TFA): methylene chloride solution and stirred at room temperature for at least 15 minutes. The reaction was continued until the blocked amino acid ester was no longer visible by TLC. Upon completion of the reaction, the reaction mixture was evaporated to dryness. A minimum volume of benzene was added and residual water removed by evaporation of the benzene-water azeotrope.
  • TFA trifluoroacetic acid
  • the reaction mixture was cooled and a clear solution formed at room temperature.
  • the solution was diluted to a total volume of 50.0 mL with dry benzene and stored in the refrigerator as a 100 ⁇ l/mL stock solution.
  • the activated polymer, the imidazole carbamate of PEG methyl ether 1900, was prepared for use in coupling to a vesicle-forming lipid, such as PE, as described below.
  • PE in addition to a strong singlet assigned to the methylene groups of the ethylene oxide chain at 3.4 ppm. Based on integration values, the ratio of methylene protons from the ethylene oxide chain to the terminal methyl group protons of the PE acyl groups was large enough to confirm a molecular weight of about 2000 for the polyethylene oxide portion of the desired product, polyethylene glycol conjugated phosphatidylethanolamine carbamate,
  • a lipid matrix consisting of PEG-PE, HSPC and cholesterol (1:3:1 by weight) was dissolved in chloroform and the solvent was then removed by rotary evaporation to produce a thin film.
  • the dried film was hydrated by addition of an ammonium sulfate buffer solution (250 mM, pH 5.5 ⁇ 0.2) heated to 55 ⁇ 5 C.
  • the sample was maintained in a hot water bath, with mechanical shaking, for about 1 hour to ensure complete hydration of the film.
  • An ammonium gradient was formed by carrying out consecutive dialysis exchanges of the extruded sample against a 10% sucrose solution at pH 5.8.
  • the extruded sample underwent three one hour exchanges and one overnight exchange in a 1:20 by volume buffer solution.
  • Liposomes with a weight ratio of 1:3: 1 PEG-PE:EPC IV 40:Chol at 100 umol/mL total lipid were prepared as in Example 3A.
  • Liposomes were prepared as described in Example 3A, except with a compositional ratio of PG:HSPC:cholesterol at 5:56:39 mol%.
  • the AZT-amino acid esters and BrdU-amino acid di-esters described in Examples 1C,D were each dissolved in 10% sucrose buffer to form stock solutions containing 5mg/mL ester.
  • To 0.2 mL of the drug-containing stock solution was added 0.2 mL of the liposomal solutions from Examples 3A.3B.
  • the resultant drug-liposomal mixture was then heated at 50° ⁇ 5°C for 0.5 hour.
  • the samples were cooled immediately in an ice bath and maintained in the ice bath for an additional 0.5-0.75 h prior to assaying for loading efficiency.
  • Example 4A The samples from Example 4A were analyzed to determine the amount of drug conjugate loaded into the liposomes. Prior to carrying out the analysis, a Sephadex G-50 gel filtration column (0.7 x 20 cm) was equilibrated with 0.9% saline. Drug-containing liposomal samples (150 uL) were loaded onto the column and the samples were eluted with saline. 300 uL fractions (10 drops) were collected and 900 uL of a 1:5 chloroform: methanol solvent system was added to each fraction.
  • the concentrations of loaded drug were determined spectrophotometrically based on their molar extinction coefficients. Quartz cuvettes were used for all samples. A wavelength of 266 nm was used for detection of AZT derivatives; a wavelength of 278 was used for derivatives of BrdU. Recoveries from the column were calculated based upon the absorbance of samples containing 10 uL of the loaded drug-liposome composition in 290 uL of saline and 900 uL of the chloroform-methanol solvent. Drug loading data is summarized in Tables I and II. Table I.
  • the compound conjugates of the present invention exhibit enhanced liposome loading levels over those of the unmodified parent compounds.
  • Preliminary experiments carried out with the corresponding BrdU mono amino acid-esters resulted in loading levels similar to those in Table II.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une composition de liposomes ainsi qu'un procédé d'administration d'un composé ayant un groupe réactif hydroxyle, à un site in vivo déterminé. Cette composition comprend une suspension de liposomes ayant un gradient de pH interne/externe, ainsi qu'un mélange dudit composé avec un produit d'addition, lequel doit être assez efficace pour maintenir le composé sous sa forme d'encapsulation par liposomes en réponse au gradient de pH.
PCT/US1996/002005 1995-02-14 1996-02-14 Composition de liposomes et procede d'administration de medicaments par liposomes Ceased WO1996025147A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49818/96A AU4981896A (en) 1995-02-14 1996-02-14 Liposome composition and method for administering liposome-loadable drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38837495A 1995-02-14 1995-02-14
US08/388,374 1995-02-14

Publications (1)

Publication Number Publication Date
WO1996025147A1 true WO1996025147A1 (fr) 1996-08-22

Family

ID=23533854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002005 Ceased WO1996025147A1 (fr) 1995-02-14 1996-02-14 Composition de liposomes et procede d'administration de medicaments par liposomes

Country Status (2)

Country Link
AU (1) AU4981896A (fr)
WO (1) WO1996025147A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035701A1 (fr) * 1997-02-11 1998-08-20 Theramark Limited Ciblage de medicament
US5882679A (en) * 1997-02-06 1999-03-16 Duke University Liposomes containing active agents aggregated with lipid surfactants
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
WO2000045845A3 (fr) * 1999-02-08 2000-12-28 Alza Corp Composition de liposomes et procede d'administration d'une substance chimique radiosensibilisante
WO2000066173A3 (fr) * 1999-05-03 2001-08-09 Infectio Recherche Inc Procedes et formulations pour cibler des agents infectieux supportant des proteines des cellules hotes
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
WO2005107712A1 (fr) 2004-05-03 2005-11-17 Hermes Biosciences, Inc. Liposomes utiles pour l'administration de medicaments
CN1319520C (zh) * 2005-02-03 2007-06-06 上海交通大学 核苷膦酸类化合物的脂质体和脂质复合物制剂
CN100345551C (zh) * 2005-02-03 2007-10-31 上海交通大学 核苷膦酸类化合物的脂质体或脂质复合物制剂的制备方法
US7309696B2 (en) * 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US8349360B2 (en) 2004-10-06 2013-01-08 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
WO2013086526A1 (fr) * 2011-12-09 2013-06-13 The Regents Of The University Of California Encapsulation liposomale de médicaments
WO2014022414A1 (fr) * 2012-07-30 2014-02-06 Coordinated Program Development, Llc Cochléates élaborés avec de la phosphatidylsérine de soja
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US20190022004A1 (en) * 2017-07-24 2019-01-24 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
US10456360B2 (en) 2015-10-16 2019-10-29 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
CN112384224A (zh) * 2018-05-07 2021-02-19 国邑药品科技股份有限公司 用于控制曲前列环素的释放的医药组合物
JP2021535922A (ja) * 2018-09-14 2021-12-23 ファルモサ バイオファーマ インコーポレイテッド 弱酸性薬物の制御放出のための医薬組成物およびその使用
RU2778886C2 (ru) * 2017-07-24 2022-08-29 Фармоса Биофарм Инк. Липосомальные композиции, содержащие слабокислотные лекарственные средства, и их применение
US12064406B2 (en) * 2019-05-14 2024-08-20 Pharmosa Biopharm Inc. Pharmaceutical composition of a weak acid drug and methods of administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361894A2 (fr) * 1988-09-28 1990-04-04 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Chargement et délivrance contrôlée de molécules dans et de liposomes
WO1992002244A1 (fr) * 1990-07-31 1992-02-20 The Liposome Company, Inc. Accumulation d'acides amines et de peptides dans des liposomes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361894A2 (fr) * 1988-09-28 1990-04-04 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Chargement et délivrance contrôlée de molécules dans et de liposomes
US5192549A (en) * 1988-09-28 1993-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of amphiphatic drug loading in liposomes by pH gradient
WO1992002244A1 (fr) * 1990-07-31 1992-02-20 The Liposome Company, Inc. Accumulation d'acides amines et de peptides dans des liposomes

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
US5882679A (en) * 1997-02-06 1999-03-16 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6296870B1 (en) 1997-02-06 2001-10-02 Duke University Liposomes containing active agents
WO1998035701A1 (fr) * 1997-02-11 1998-08-20 Theramark Limited Ciblage de medicament
WO1999051202A3 (fr) * 1998-04-02 1999-11-18 Sequus Pharm Inc Composition de liposomes et methode d'administration de quinolone
AU763989B2 (en) * 1998-04-02 2003-08-07 Alza Corporation Quinolone containing liposomes and their use as antibacterial agents
WO2000045845A3 (fr) * 1999-02-08 2000-12-28 Alza Corp Composition de liposomes et procede d'administration d'une substance chimique radiosensibilisante
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
WO2000066173A3 (fr) * 1999-05-03 2001-08-09 Infectio Recherche Inc Procedes et formulations pour cibler des agents infectieux supportant des proteines des cellules hotes
AU768685B2 (en) * 1999-05-03 2003-12-18 Infectio Recherche Inc. Methods and formulations for targeting infectious agents bearing host cell proteins
US7357930B1 (en) 1999-05-03 2008-04-15 Infectio Recherche Inc. Methods and formulations for targeting infectious agents bearing host cell proteins
US7309696B2 (en) * 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US10350201B2 (en) 2004-05-03 2019-07-16 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US11052079B2 (en) 2004-05-03 2021-07-06 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US8147867B2 (en) 2004-05-03 2012-04-03 Hermes Biosciences, Inc. Liposomes useful for drug delivery
US8329213B2 (en) 2004-05-03 2012-12-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
EP4218730A1 (fr) 2004-05-03 2023-08-02 Ipsen Biopharm Ltd. Liposomes utiles pour l'administration de médicaments
US10722508B2 (en) 2004-05-03 2020-07-28 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US10413510B2 (en) 2004-05-03 2019-09-17 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
WO2005107712A1 (fr) 2004-05-03 2005-11-17 Hermes Biosciences, Inc. Liposomes utiles pour l'administration de medicaments
US8703181B2 (en) 2004-05-03 2014-04-22 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
US9782349B2 (en) 2004-05-03 2017-10-10 Ipsen Biopharma Ltd. Liposomes useful for drug delivery
US8992970B2 (en) 2004-05-03 2015-03-31 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
US9737528B2 (en) 2004-05-03 2017-08-22 Ipsen Biopharm Ltd. Liposomes useful for drug delivery to the brain
EP3173073A1 (fr) 2004-05-03 2017-05-31 Merrimack Pharmaceuticals, Inc. Liposomes pour l'administration de médicament
US9717723B2 (en) 2004-05-03 2017-08-01 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US9724303B2 (en) 2004-05-03 2017-08-08 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US9730891B2 (en) 2004-05-03 2017-08-15 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US8709474B2 (en) 2004-10-06 2014-04-29 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
US8349360B2 (en) 2004-10-06 2013-01-08 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
CN100345551C (zh) * 2005-02-03 2007-10-31 上海交通大学 核苷膦酸类化合物的脂质体或脂质复合物制剂的制备方法
CN1319520C (zh) * 2005-02-03 2007-06-06 上海交通大学 核苷膦酸类化合物的脂质体和脂质复合物制剂
WO2013086526A1 (fr) * 2011-12-09 2013-06-13 The Regents Of The University Of California Encapsulation liposomale de médicaments
US11964019B2 (en) 2012-07-30 2024-04-23 Rutgers, The State University Of New Jersey Cochleates made with soy phosphatidylserine
WO2014022414A1 (fr) * 2012-07-30 2014-02-06 Coordinated Program Development, Llc Cochléates élaborés avec de la phosphatidylsérine de soja
US9370572B2 (en) 2012-07-30 2016-06-21 Aquarius Biotechnologies, Inc Cochleates made with soy phosphatidylserine
US10716860B2 (en) 2012-07-30 2020-07-21 Matinas Biopharma Nanotechnologies, Inc. Cochleates made with soy phosphatidylserine
US12409227B2 (en) 2012-07-30 2025-09-09 Rutgers, The State University Of New Jersey Cochleates made with soy phosphatidylserine
US9775907B2 (en) 2012-07-30 2017-10-03 Matinas Biopharma Nanotechnologies, Inc. Cochleates made with soy phosphatidylserine
US10456360B2 (en) 2015-10-16 2019-10-29 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
US12059497B2 (en) 2015-10-16 2024-08-13 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
US10993914B2 (en) 2015-10-16 2021-05-04 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
US20190022004A1 (en) * 2017-07-24 2019-01-24 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
US11964050B2 (en) 2017-07-24 2024-04-23 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
AU2018307509B2 (en) * 2017-07-24 2021-04-29 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
WO2019023092A1 (fr) 2017-07-24 2019-01-31 Pharmosa Biopharm Inc. Compositions de liposomes comprenant des médicaments à base d'acide faible et utilisations de celles-ci
KR102337566B1 (ko) * 2017-07-24 2021-12-14 파모사 바이오팜 인코포레이티드 약산성 약물을 포함하는 리포솜 조성물 및 이의 용도
US12220483B2 (en) 2017-07-24 2025-02-11 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
TWI728255B (zh) * 2017-07-24 2021-05-21 國邑藥品科技股份有限公司 包含弱酸藥物之脂質體組成物及其用途
KR20200016976A (ko) * 2017-07-24 2020-02-17 파모사 바이오팜 인코포레이티드 약산성 약물을 포함하는 리포솜 조성물 및 이의 용도
IL272187B (en) * 2017-07-24 2022-08-01 Pharmosa Biopharm Inc Liposome preparations containing weak acid drugs and uses thereof
RU2778886C2 (ru) * 2017-07-24 2022-08-29 Фармоса Биофарм Инк. Липосомальные композиции, содержащие слабокислотные лекарственные средства, и их применение
CN111372580A (zh) * 2017-07-24 2020-07-03 国邑药品科技股份有限公司 包含弱酸药物的脂质体组合物及其用途
US11229616B2 (en) 2018-05-07 2022-01-25 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of treprostinil
CN112384224A (zh) * 2018-05-07 2021-02-19 国邑药品科技股份有限公司 用于控制曲前列环素的释放的医药组合物
US11833125B2 (en) 2018-05-07 2023-12-05 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of treprostinil
RU2796305C2 (ru) * 2018-05-07 2023-05-22 Фармоса Биофарм Инк. (Pharmosa Biopharm Inc.) Фармацевтическая композиция для контролированного высвобождения трепростинила
JP7140418B2 (ja) 2018-05-07 2022-09-21 ファルモサ バイオファーマ インコーポレイテッド トレプロスチニルの制御放出のための医薬組成物
CN112384224B (zh) * 2018-05-07 2024-06-07 国邑药品科技股份有限公司 用于控制曲前列环素的释放的医药组合物
JP2021523157A (ja) * 2018-05-07 2021-09-02 ファルモサ バイオファーマ インコーポレイテッド トレプロスチニルの制御放出のための医薬組成物
JP7315982B2 (ja) 2018-09-14 2023-07-27 ファルモサ バイオファーマ インコーポレイテッド 弱酸性薬物の制御放出のための医薬組成物およびその使用
JP2023123843A (ja) * 2018-09-14 2023-09-05 ファルモサ バイオファーマ インコーポレイテッド 弱酸性薬物の制御放出のための医薬組成物およびその使用
EP3849560A4 (fr) * 2018-09-14 2022-06-08 Pharmosa Biopharm Inc. Composition pharmaceutique destinée à la libération contrôlée de médicaments à base d'acide faible et utilisations correspondantes
JP2021535922A (ja) * 2018-09-14 2021-12-23 ファルモサ バイオファーマ インコーポレイテッド 弱酸性薬物の制御放出のための医薬組成物およびその使用
US20250241856A1 (en) * 2018-09-14 2025-07-31 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
US12064406B2 (en) * 2019-05-14 2024-08-20 Pharmosa Biopharm Inc. Pharmaceutical composition of a weak acid drug and methods of administration

Also Published As

Publication number Publication date
AU4981896A (en) 1996-09-04

Similar Documents

Publication Publication Date Title
WO1996025147A1 (fr) Composition de liposomes et procede d'administration de medicaments par liposomes
CA1334846C (fr) Derives lipidiques de nucleosides antiviraux, leur incorporation dans des liposomes et methode pour leur utilisation
AU668873B2 (en) Antiviral liponucleosides: treatment of hepatitis B
EP0688329B1 (fr) Nouveaux conjugues phospholipide-saccharide
US6448392B1 (en) Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5334391A (en) Intracellularly cleavable compounds
US5194654A (en) Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6252060B1 (en) Antiviral liponucleosides: treatment of hepatitis B
JP2538474B2 (ja) 生物学的活性分子の細胞内配達のための陽イオン脂質
US6011020A (en) Nucleic acid ligand complexes
EP0964690B1 (fr) Conjugues de peptide-lipide, liposomes et apport de medicaments par des liposomes
US6599887B2 (en) Methods of treating viral infections using antiviral liponucleotides
KR20010114247A (ko) 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트
WO1989002733A1 (fr) Analogues de nucleosides liposomiques pour le traitement du sida
EP1426044B1 (fr) Utilisation d'esters de L-carnitine ou de L-carnitine d'alcanoyl comme lipides cationiques pour l'administration intracellulaire de composés thérapeutiques
US20020035082A1 (en) Carbohydrate based lipid compositions and supramolecular structures comprising same
US5817638A (en) Antiviral liponucleosides: treatment of hepatitis B
US20030147944A1 (en) Lipid carrier compositions with protected surface reactive functions
Van Borssum Waalkes et al. In vivo distribution and antitumour activity of liposomal 3′, 5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine
Vodovozova et al. Synthesis of diglyceride conjugate of selectin ligand SiaLeX as a vector for targeting of drug-loaded liposomes
Sabloff Characterization and intracellular delivery of lipid-drug conjugates
CA2353832A1 (fr) Conjugues de lipides et de medicaments antimicrobiens ou antineoplasiques
PT91101B (pt) Processo de preparacao de derivados lipidos de nucleosidos antivirais, de suspensoes de lipossomas e de composicoes farmaceuticas
Chang Interaction and entrapment of suramin and related compounds with phospholipid vesicles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA